Mentor Capital Inc. - MNTR - QI Relationship

Mentor Capital, Inc and CI Companies

66 Days Left on $1 Call

About Mentor Capital MNTR - QI Relationship About MNTR Summary Data Management Team Professional Support Philosophy Ethics Corporate Governance The Investor's Corner 2009 Annual Financials (Subject to Audit Adjustments) 2008 Audit 15(c) 2-11 Analysts' Coverage $5 / Share - Sr. Securities Analyst $28 / Share by 2012, BioMed Reports Cancer Imm Index Information Visit Portfolio Companies

MNTR - QI Relationship

Δ Mentor Capital QI Stock Purchase Contract

The Mentor Capital Cancer Immunotherapy Index^©

Our Science Explained

For Email Marketing you can trust

Site Search

Home

Chairman's Letters

◦	Welcome to the Team Leading the Cancer Fight
◦	Chairman's 2009 Recap with $0.91/sh Portfolio Gains

◦	List of All Releases
◦	MNTR Sees Shift To Public Acceptance
◦	Cancer Index at New High with 12 Yr Exclusive Period in Health Bill
◦	Provectus Pharmaceuticals (PVCT) added to Cancer Immunotherapy Index.
◦	Mentor Capital Cancer Index Start Oversubscribed
◦	Mentor has $0.91/share Portfolio Gains (non-GAAP)
◦	MNTR Invests in 10 Cancer Index Companies
◦	MNTR Retains Investment Bank to Assist Roll Out Cancer Immunotherapy Index Fund
◦	2010 Actively Managed Cancer Immunotherapy Index Announced by MNTR
◦	University Agreement Indicates Broad Cancer Application for QI Treatment
◦	New Lab, Filings and JV Talks
◦	MNTR Presents In NYC
◦	MNTR Leads Cancer Index
◦	Start of FDA Trials
◦	QI Announces MNTR
◦	MNTR Acquires First 20% of QI
◦	MNTR Calls $3 Million Tranche
◦	MNTR Initiates Trading

MNTR In The News

◦	All News Articles
◦	Mentor Capital Update in Seeking Alpha
◦	MNTR Top Gainer in Cancer Index
◦	MNTR Stealth Cancer Play
◦	MNTR Forecast at $28.60 in 2012
◦	Quantum Leap In Funding

Cancer Resources

Information For Brokers

Shareholder Updates

FAQ

All PDF documents will open a new browser window

©2010 Mentor Capital Inc. | All Rights Reserved

Safe Harbor Statement Site Map